Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study wi...

Descripción completa

Detalles Bibliográficos
Autores: Herrera-Hidalgo, Laura, Muñoz, Patricia, Álvarez-Uría, Ana, Alonso-Menchén, David, Luque-Marquez, Rafael, Gutiérrez-Carretero, Encarnación, Fariñas, María Del Carmen, Miró, Jose Maria, Goenaga, Miguel Angel, López-Cortés, Luis Eduardo, Angulo-Lara, Basilio, Boix-Palop, Lucia, de Alarcón, Arístides, Arrizabalaga-Asenjo, Maria, Cifuentes Luna, Carmen, Nuñez Morcillo, Juana, Pérez Seco, Mª Cruz, Villoslada Gelabert, Aroa, Ruiz de Gopegui-Bordes, Enrique, Ribas del Blanco, Maria Àngels, Vidal Bonet, Laura, Vives-Borrás, Miquel
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/25372
Acceso en línea:https://hdl.handle.net/20.500.13003/25372
Access Level:acceso abierto
Palabra clave:Penicillinum
Cefazolin
Endocarditis
Methicillin-Resistant Staphylococcus aureus
Cefazolina
Staphylococcus aureus Resistente a Meticilina
Antistaphylococcal penicillin
Infective endocarditis
Methicillin-susceptible Staphylococcus aureus
Descripción
Sumario:Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective.

Similares en LA Referencia